e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relapse-free cure from multidrug-resistant tuberculosis in Germany
Jan Heyckendorf, Frank van Leth, Barbara Kalsdorf, Ioana D. Olaru, Gunar Günther, Helmut J.F. Salzer, Elena Terhalle, Thierry Rolling, Georg Glattki, Marius Müller, Maren Schuhmann, Korkut Avsar, Christoph Lange
Source:
Eur Respir J, 51 (2) 1702122; 10.1183/13993003.02122-2017
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jan Heyckendorf, Frank van Leth, Barbara Kalsdorf, Ioana D. Olaru, Gunar Günther, Helmut J.F. Salzer, Elena Terhalle, Thierry Rolling, Georg Glattki, Marius Müller, Maren Schuhmann, Korkut Avsar, Christoph Lange. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur Respir J, 51 (2) 1702122; 10.1183/13993003.02122-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Surgical treatment of multidrug-resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003
Risk of mortality of extensively drug-resistant tuberculosis (XDR-TB) in Italy and Germany
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008
Multidrug-resistant tuberculosis (MDR-TB)
Source: Breathe 2010; 6: 283
Year: 2010
Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 380s
Year: 2006
Comorbidome in multidrug-resistant tuberculosis patients
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020
Multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in Romania
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe
Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017
Year: 2017
Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe
Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017
Year: 2017
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011
Analysis of multidrug-resistant tuberculosis
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept